Following an investigation, a genetics journal has pulled six cancer papers published this year for plagiarizing from other sources.
According to an excerpt from the retraction notice in Genetics and Molecular Research, the journal has “strong reason to believe that the peer review process was [a] failure,” and has alerted the authors’ institutions.
Science has retracted a high-profile immunology paper after a probe concluded the corresponding author had committed misconduct.
The paper — which initially caught media attention for suggesting a protein could help boost the immune system’s ability to fight off tumors — has been under a cloud of suspicion since last year, when the journal tagged it with an expression of concern, citing a university investigation.
That investigation — at Imperial College London — has concluded that the paper contained problematic figures that were the result of research misconduct. All were prepared by last and corresponding author Philip Ashton-Rickardt, who took full responsibility. Even though the paper was published in 2015, some original blots and accompanying details have disappeared.
A journal has retracted a paper after a reader pointed out some of the data looked familiar — and the authors never responded to the allegations.
According to the retraction notice in the International Journal of Molecular Medicine, the reader showed the journal that the histological data in two of the figures were from another published paper by different researchers. But when the journal contacted the authors on several occasions, they didn’t hear back.
An investigation into the lab of a prominent cancer researcher in British Columbia has revealed nearly 30 acts of misconduct.
As we detail in our latest feature for Science, the investigation, at the University of British Columbia (UBC), uncovered 29 instances of scientific misconduct, 16 of which were characterized as “serious,” according to university correspondence obtained by Retraction Watch.
The researcher, Sandra Dunn, is prominent in her field, but she left UBC in 2015 under unclear circumstances, shortly after it concluded its investigation. Dunn now heads a private company, Phoenix Molecular Designs, which says it develops therapies for cancer patients and lists local charities among its “partners and supporters.” While at UBC, Dunn obtained at least $1.1 million dollars in Canadian federal funding, some of which was used to support the falsified studies.
A lab at the University of California, Los Angeles has retracted two papers for duplicated images.
These retractions — in the Journal of Immunology — represent the second and third retractions for the lab head; he lost another paper after one of his former students confessed to manipulating images.
Unfortunately, Suzuki’s admission in 2014 wasn’t the end of the troubles for lab head Benjamin Bonavida, who recently issued two additional retractions in the Journal of Immunology, only one of which includes Suzuki as a co-author.
Bonavida told us the university received allegations (he’s not sure from who) that some of the control gels were duplicated; he didn’t agree, but couldn’t produce the original gels to disprove it. We asked if any more retractions were coming from Bonavida, who has since retired from running a lab:
Last year, a cancer researcher wrote to the Journal of Biological Chemistry, asking to correct one of his papers. The journal responded by requesting the raw data used to prepare his figures. Then, in a follow-up request, it asked for raw data behind the figures in 20 additional published articles.
And when all was said and done six months later, Jin Cheng ended up with far more than just a single correction: Last month, the journal issued withdrawals for 19 of his papers — including the paper he originally asked to correct — along with one correction.
We’ve pieced together some clues about what happened after reviewing correspondence between representatives of JBC and Moffitt Cancer Center, where Cheng conducted his research. A spokesperson for Moffitt confirmed that the retractions did not initiate from an institutional investigation — but that the institution is now conducting one.
That’s not the way retractions typically happen: Often, journals don’t have the resources to conduct investigations themselves, so institutions mostly take the lead in double-checking papers and, if necessary, contacting the journal to initiate a retraction. Here, it seems the opposite took place.
Last week, we learned a 2016 paper heavily discussed on PubPeer might be retracted — today, we learned that Nature Cell Biology has indeed pulled the paper, citing inappropriate image modifications.
As we reported last week, a comment on PubPeer flagged as coming from an author said they had requested a retraction. A representative of National Taiwan University (NTU) told us the first author had resigned, and the paper was under investigation — an investigation which included the last author, a prominent researcher who is also a vice president at another institution in Taiwan.
Two sets of authors based largely at Harvard Medical School have each retracted a paper for duplication in the same journal.
Both papers — which are more than a decade old — were pulled in The Journal of Clinical Investigation on November 1 by their respective corresponding authors.
One paper’s last author told us it was difficult to identify how the duplications occurred since the study took place so long ago, but added that multiple experiments had corroborated the results.
However, the latest retraction affects a paper published eight years later in the International Journal of Oncology. Its coauthors include Bhagavathi Narayanan, Narayanan K. Narayanan and Rajkishen Narayanan; we haven’t been able to uncover if there is a relation between them.